<DOC>
	<DOC>NCT01308021</DOC>
	<brief_summary>The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.</brief_summary>
	<brief_title>Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
	<criteria>Age between 18 and 50 years Subject has given written informed consent The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status Male or non pregnant, nonlactating female Female unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or post menopausal (defined as a minimum of one year since the last menstrual period)) Allergy &gt; 2 years Subjects with current immunotherapy or subjects who underwent a previous immunotherapy within the last 2 years Subjects with perennial asthma Subjects with a VC &lt; 80% and FEV1 &lt; 70% Subjects requiring controller medication against asthma (bronchodilator nebulised drugs or local or systemic corticosteroids) Documented evidence of chronic sinusitis (as determined by investigator) Subjects with a history of hepatic or renal disease Subjects symptomatic to perennial inhalant allergens Subject with malignant disease, autoimmune disease Female subjects who are pregnant, lactating, or of childbearing potential and not protected from pregnancy by a sufficiently reliable method (OCs, IUD, ...) Any chronic disease, which may impair the subject's ability to participate in the trial (i.e. severe congestive heart failure, active gastric ulcer, inflammatory bowel disease, uncontrolled diabetes mellitus, etc…) Subjects requiring betablockers medication Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants) Subject with febrile illness (&gt; 37.5°C, oral) A known positive serology for HIV1/2, HBV or HCV The subject is immunocompromised by medication or illness, has received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry Receipt of blood or a blood derivative in the past 6 months preceding trial entry Regular consumption of corticoids (oral, topic or nasal) or of antihistaminic drugs within 4 weeks preceding the trial Any consumption of corticoids (oral, topic or nasal) or of antihistaminic drugs within 1 week preceding the trial Use of longacting antihistamines Any condition which could be incompatible with protocol understanding and compliance Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship Unreliable subjects including noncompliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give informed consent or to abide by the requirements of the protocol Participation in another clinical trial and/or treatment with an experimental drug within the last 2 years A history of hypersensitivity to the excipients Rhinitis medicamentosa, nonspecific rhinitis (to food dye, preservative agent…) Subjects without means of contacting the investigator rapidly in case of emergency, or not able to be contacted rapidly by the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Hypersensitivity</keyword>
	<keyword>Immune system disorder</keyword>
</DOC>